1.1404

8.06% -0.0996

Scienture Holdings Inc (SCNX)

Overview News Price History Discussions Forecast

Scienture Holdings Inc stock is traded at $1.1404, with a volume of 131.85K. It is down -8.06% in the last 24 hours and down -54.03% over the past month.

Previous Close:

$1.24

Open:

$1.2

24h Volume:

131.85K

Relative Volume:

0.05

Market Cap:

$10.43M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-30.91%

1M Performance:

-54.03%

6M Performance:

-83.81%

1Y Performance:

+0.00%

1-Day Range:

$1.12

$1.2199

1-Week Range:

$1.12

$1.6627

52-Week Range:

$1.00

$9.55

Scienture Holdings Inc Stock (SCNX) Company Profile

Name

Scienture Holdings Inc

Sector

Healthcare (1161)

Industry

Pharmaceutical Retailers (9)

Phone

(800) 261 0281

Address

2420 BRUNELLO TRACE, LUTZ

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SCNX's Discussions on Twitter

Compare SCNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCNX Scienture Holdings Inc	1.14	10.43M	0	0	0	0.00
WBA Walgreens Boots Alliance Inc	11.05	9.59B	147.66B	-8.64B	-363.00M	-10.01
WGRX Wellgistics Health Inc	4.28	228.04M	0	0	0	0.00
HITI High Tide Inc	1.8697	150.55M	376.07M	-22.41M	18.73M	-0.298
PETS Petmed Express Inc	3.6045	75.40M	270.52M	-6.08M	17.42M	-0.2944

Scienture Holdings Inc Stock (SCNX) Latest News

09:14 AM

Scienture Holdings gears up for specialty pharma launches - Investing.com

09:14 AM

08:46 AM

Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks

08:46 AM

08:26 AM

Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView

08:26 AM

Mar 26, 2025

Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register

Mar 26, 2025

Mar 25, 2025

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times

Mar 25, 2025

Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan

Mar 25, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times

Mar 19, 2025

Organovo Announces Reverse Stock Split - The Manila Times

Mar 19, 2025

FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan

Mar 19, 2025

Mar 18, 2025

Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mar 18, 2025

FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics

Mar 18, 2025

What's Going On With Scienture Shares Tuesday?Scienture Holdings (NASDAQ:SCNX) - Benzinga

Mar 18, 2025

FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times

Mar 18, 2025

Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph

Mar 18, 2025

Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener

Mar 18, 2025

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025

Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan

Mar 18, 2025

Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail

Mar 18, 2025

Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail

Mar 18, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 17, 2025

4 Quantum Computing Stocks on Watch Today as GTC 2025 Kicks Off - The Globe and Mail

Mar 17, 2025

Mar 15, 2025